Table 2.
Arrhythmias during exposure to PAF following previous exposure to PAF or vehicle
| Previous solution | PAF (nmol) | |||||
|---|---|---|---|---|---|---|
| 0 | 0.1 | 1 | 10 | 100 | ||
| VPBs | Vehicle | 17 | 25 | 25 | 8 | 33 |
| PAF | 33 | 58 | 75* | 83* | 91* | |
| Bigeminy | Vehicle | 17 | 25 | 25 | 17 | 42 |
| PAF | 42 | 58 | 67* | 73* | 82 | |
| Salvos | Vehicle | 8 | 8 | 0 | 0 | 8 |
| PAF | 42 | 25 | 42 | 45* | 55* | |
| VT | Vehicle | 0 | 0 | 0 | 0 | 0 |
| PAF | 33 | 42 | 42 | 45* | 45* | |
| VF | Vehicle | 0 | 0 | 0 | 0 | 0 |
| PAF | 8 | 8 | 17 | 9 | 9 | |
The data represent arrhythmia incidence (%), during identically timed exposure to PAF, following previous exposure to PAF or vehicle, according to the protocol in Figure 1. PAF (0–100 nmol) was delivered selectively to the left coronary bed. 0 nmol refers to PAF vehicle; n=12 per group.
*
P<0.05 versus the group previously exposed to vehicle.